Guangxi Wuzhou Zhongheng Group Co., Ltd. Class ASSE: 600252

Announcement on the Ethical Approval Obtained for the Phase II Clinical Trial of Ferrous Ion Adsorbed Carbon Nanoparticle Suspension Injection Combined with Radiotherapy by a Holding Sub-subsidiary

· Issued by Guangxi Wuzhou Zhongheng Group Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on the Ethical Approval Obtained for the Phase II Clinical Trial of Ferrous Ion Adsorbed Carbon Nanoparticle Suspension Injection Combined with Radiotherapy by a Holding Sub-subsidiary

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis